Dec 10, 2024
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
Sep 13, 2024
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients
Feb 07, 2024
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication
Feb 09, 2021
Moberg Pharmas Year-end report 2020
Jan 29, 2021
New number of shares and votes in Moberg Pharma AB (publ)
Jan 29, 2021
Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex Asea
Nov 16, 2020
OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing
Nov 10, 2020
Extended fiscal year July 2019 - December 2020 Interim report July - September 2020
Nov 06, 2020
Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI)
Oct 14, 2020
Moberg Pharma intends to submit a registration application in Europe in 2021
Aug 11, 2020
Moberg Pharma: Interim report April - June 2020
Aug 04, 2020
Moberg Pharma's Interim report for July 2019 - June 2020 to be published on August 11 - Invitation to teleconference
Jun 30, 2020
New number of Shares and Votes in Moberg Pharma AB (publ)
Jun 25, 2020
Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study
May 29, 2020
New Number of Shares and Votes in Moberg Pharma AB (publ)
May 12, 2020
Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020
Mar 23, 2020
Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015
Feb 04, 2020
Moberg Pharma's Interim Report to be Published on February 11 - Invitation to Teleconference
Jan 22, 2020
Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015
Dec 12, 2019
Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015